Cargando…
PPARγ maintains ERBB2-positive breast cancer stem cells
Overexpression of the adverse prognostic marker ERBB2 occurs in 30% of breast cancers and is associated with aggressive disease and poor outcomes. Our recent findings have shown that NR1D1 and the peroxisome proliferator-activated receptor-γ (PPARγ)-binding protein (PBP) act through a common pathway...
Autores principales: | Wang, X, Sun, Y, Wong, J, Conklin, D S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898098/ https://www.ncbi.nlm.nih.gov/pubmed/23770845 http://dx.doi.org/10.1038/onc.2013.217 |
Ejemplares similares
-
Peroxisome proliferator-activated receptor-γ protects ERBB2-positive breast cancer cells from palmitate toxicity
por: Kourtidis, Antonis, et al.
Publicado: (2009) -
Pparγ1 Facilitates ErbB2-Mammary Adenocarcinoma in Mice
por: Jiao, Xuanmao, et al.
Publicado: (2021) -
Cholesterol content in cell membrane maintains surface levels of ErbB2 and confers a therapeutic vulnerability in ErbB2-positive breast cancer
por: Zhang, Jinrui, et al.
Publicado: (2019) -
The deubiquitylase USP2 maintains ErbB2 abundance via counteracting endocytic degradation and represents a therapeutic target in ErbB2-positive breast cancer
por: Zhang, Jinrui, et al.
Publicado: (2020) -
PPARγ maintains the metabolic heterogeneity and homeostasis of renal tubules
por: Lyu, Zhongshi, et al.
Publicado: (2018)